BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8284687)

  • 1. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2.
    Buter J; Sleijfer DT; van der Graaf WT; de Vries EG; Willemse PH; Mulder NH
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):16-21. PubMed ID: 8284687
    [No Abstract]   [Full Text] [Related]  

  • 2. European studies of interleukin-2 in metastatic renal cell carcinoma.
    Atzpodien J; Kirchner H; Hänninen EL; Körfer A; Fenner M; Menzel T; Deckert M; Franzke A; Jonas U; Poliwoda H
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):22-6. PubMed ID: 8284688
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 4. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
    Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J; Kirchner H; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of renal cell carcinoma with systemic administration of intermediate doses of recombinant human interleukin-2 alone. Recombinant Human Interleukin-2 (S-6820) Research Group on Renal Cell Carcinoma.
    Aso Y; Tazaki H; Umeda T; Marumo K
    Prog Clin Biol Res; 1989; 303():681-8. PubMed ID: 2675018
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2).
    Huland E; Heinzer H; Huland H
    Anticancer Res; 1999; 19(4A):2679-83. PubMed ID: 10470219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 10. In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2.
    Meffert M; Schomburg A; Hänninen EL; Menzel T; Vocke S; Dallmann I; Grosse J; Duensing S; Buer J; Kirchner H
    Anticancer Res; 1995; 15(1):127-32. PubMed ID: 7733621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in management of disseminated renal cell carcinoma.
    Javadpour N
    Prog Clin Biol Res; 1988; 277():85-91. PubMed ID: 3263656
    [No Abstract]   [Full Text] [Related]  

  • 12. [Preliminary findings on clinical and immunological effects of subcutaneously administered interleukin-2 + alpha-interferon combination in the treatment of advanced renal carcinoma].
    Buda F; Buda C; Croatto T; Costa B; Aragona P; Tuveri G
    Recenti Prog Med; 1995; 86(7-8):304-5. PubMed ID: 7569288
    [No Abstract]   [Full Text] [Related]  

  • 13. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
    J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive cellular therapy of renal carcinoma.
    West WH
    Prog Clin Biol Res; 1989; 303():689-96. PubMed ID: 2789392
    [No Abstract]   [Full Text] [Related]  

  • 15. [Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program].
    Tourani JM; Jaillon-Abraham C; Lucas V; Chrétien Y; Mayeur D; Di Palma M; Boaziz C; Grise P; Varette C; Pavlovitch JM; Larregain D; Ecstein E; Untereiner M; Andrieu JM
    Bull Cancer; 1997 Apr; 84(4):351-6. PubMed ID: 9238157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
    Huland E; Heinzer H; Huland H
    Folia Biol (Praha); 2000; 46(6):241-50. PubMed ID: 11140857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapeutic treatment for metastatic renal carcinoma].
    Hidalgo Pardo F; Gutiérrez Sanz-Gadea C; Rebassa Llull MJ; García Bueno JM; Mus Malleu A; Losada González GP; Ozonas Moragues M
    Actas Urol Esp; 1998 Jan; 22(1):29-33. PubMed ID: 9542189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.
    Duensing S; Hadam M; Körfer A; Schomburg A; Menzel T; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
    Mol Biother; 1992 Dec; 4(4):170-3. PubMed ID: 1282326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
    Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical contrast reactions associated with systemic interleukin-2 therapy.
    Fishman JE; Aberle DR; Moldawer NP; Belldegrun A; Figlin RA
    AJR Am J Roentgenol; 1991 Apr; 156(4):833-4. PubMed ID: 2003450
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.